Delving into the Latest Updates on Human Papillomavirus Type 11 Inhibitors(Boehringer Ingelheim Ltd) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

HPV-11 E1-E2 inhibitors, human papillomavirus type 11 inhibitors(Boehringer Ingelheim Ltd)

Target

HPV E1 x HPV E2

Mechanism

HPV E1 inhibitors(HPV E1 inhibitors), HPV E2 inhibitors(HPV E2 inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Human Papillomavirus Infection

Originator Organization

Boehringer Ingelheim GmbH

Active Organization-

Inactive Organization

Boehringer Ingelheim GmbH

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

ABSTRACT The human papillomavirus type 11 (HPV-11) L1 major capsid protein can be trypsinized to generate recombinant capsomeres that retain HPV genotype-restricted capsid antigenicity (M. Li, T. P. Cripe, P. A. Estes, M. K. Lyon, R. C. Rose, and R. L. Garcea, J. Virol. 71:2988–2995, 1997). In the present study, HPV-11 virion-neutralizing monoclonal antibodies H11.F1 and H11.H3, previously characterized as recognizing two distinct HPV-11 capsid-neutralizing antigenic domains (S. W. Ludmerer, D. Benincasa, and G. E. Mark III, J. Virol. 70:4791–4794, 1996), were each found to be highly immunoreactive with trypsin-generated capsomeres in an enzyme-linked immunosorbent assay (ELISA). Capsomeres were used to generate high-titer polyclonal immune sera that demonstrated HPV genotype-restricted reactivity by ELISA. The capsomere antisera were then tested in an in vitro infectivity assay and found to neutralize HPV-11 virions. In this assay, HPV-11 capsomere polyclonal antisera exhibited neutralization titers (10 −5 to 10 −6 ) comparable to those obtained with a virion-neutralizing antiserum raised previously against intact HPV-11 VLPs (R. C. Rose, R. C. Reichman, and W. Bonnez, J. Gen. Virol. 75:2075–2079, 1994). These results indicate that highly immunogenic, genotype-restricted HPV capsid-neutralizing antigenic domains are contained entirely within capsomeres. Thus, capsomeres may be viable vaccine candidates for the prevention of HPV disease.

100 Deals associated with Human Papillomavirus Type 11 Inhibitors(Boehringer Ingelheim Ltd)

Login to view more data